Synta plans cautious approach to Phase III for its HSP inhibitor
This article was originally published in Scrip
Executive Summary
Synta Pharmaceuticals is sufficiently encouraged by interim Phase II data for its heat shock protein inhibitor ganetespib (STA-9090) in non-small cell lung cancer to take the product into a Phase IIb/III trial in this indication next quarter. The promising results are a boon for the company which suffered disappointment with its former lead product elesclomol in melanoma and they will strengthen its hand as it seeks a licensing partner.